Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Basicity of Heterocyclic Aromatic Amines01:25

Basicity of Heterocyclic Aromatic Amines

Heterocyclic amines, where the N atom is a part of an alicyclic system, are similar in basicity to alkylamines. Interestingly, the heterocyclic amine having a nitrogen atom as part of an aromatic ring has much less basicity than its corresponding alicyclic counterpart. For this reason, as presented in Figure 1, piperidine (pKb = 2.8) is significantly more basic than pyridine (pKb = 8.8).
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural basis of the regulation by CDK11 kinase of early spliceosome activation and evidence for its proofreading by DHX15 helicase.

Nature communications·2026
Same author

2'-O-methylation-dependent installation of N<sup>2</sup>-methylguanosine in the U6 internal stem loop facilitates efficient spliceosome assembly.

Nature communications·2026
Same author

Controlled route to active turbulence: filling an activity spot with topological defects.

Soft matter·2026
Same author

The dual G9a inhibitor and histamine H3 receptor antagonist A-366 improves repetitive and social behaviors and attenuates neuroinflammation in BTBR T + tf/J mice.

Scientific reports·2026
Same author

Multitargeted Aza-Arylcarboxamides for Neurodegenerative Diseases: Potent Histamine H<sub>3</sub> Receptor Ligands with Anticholinesterase and Metal-Chelating Activities.

ACS chemical neuroscience·2026
Same author

Neuroinflammatory Human Brain Organoids Enable Comprehensive Drug Screening Studies: Fingolimod and its Analogues in Focus.

Current medicinal chemistry·2025

Related Experiment Video

Updated: Jun 16, 2026

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Acidic elements in histamine H(3) receptor antagonists.

Kerstin Sander1, Yvonne von Coburg, Jean-Claude Camelin

  • 1Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, ZAFES/LiFF/CMP, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany.

Bioorganic & Medicinal Chemistry Letters
|February 9, 2010
PubMed
Summary

Researchers explored novel human histamine H(3) receptor (hH(3)R) antagonists by incorporating acidic functionalities. These compounds demonstrated nanomolar affinities for hH(3)R, expanding the known pharmacophore blueprint for this receptor.

More Related Videos

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

Determination of the Gas-phase Acidities of Oligopeptides
11:00

Determination of the Gas-phase Acidities of Oligopeptides

Published on: June 24, 2013

Related Experiment Videos

Last Updated: Jun 16, 2026

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

Determination of the Gas-phase Acidities of Oligopeptides
11:00

Determination of the Gas-phase Acidities of Oligopeptides

Published on: June 24, 2013

Area of Science:

  • Medicinal Chemistry
  • Pharmacology

Background:

  • Histamine H(3) receptor (hH(3)R) antagonists often utilize a basic moiety to enhance binding affinity.
  • Exploring alternative functional groups is crucial for developing novel therapeutic agents.

Purpose of the Study:

  • To investigate the impact of incorporating acidic moieties into known hH(3)R antagonist pharmacophores.
  • To determine if hH(3)R tolerates acidic functionalities and to assess the resulting binding affinities.

Main Methods:

  • Synthesis of novel compounds featuring acidic moieties with varying pK(a) values.
  • Evaluation of ligand affinity for the human histamine H(3) receptor (hH(3)R) in the nanomolar concentration range.
  • Testing selected ligands for dual activity against human peroxisome proliferator-activated receptor (hPPAR).

Main Results:

  • The hH(3)R was found to tolerate acidic functionalities when integrated into the common pharmacophore blueprint.
  • Designed ligands exhibited hH(3)R affinities within the nanomolar range, influenced by the acidic group's features.
  • Selected compounds failed to demonstrate dual antagonism for hH(3)R and hPPAR.

Conclusions:

  • Acidic moieties can be successfully incorporated into hH(3)R antagonist design, expanding the chemical space for receptor ligands.
  • Ligand affinity is modulated by the specific acidic, electronic, and steric properties of the incorporated functionalities.
  • The developed compounds are selective for hH(3)R and do not exhibit dual activity with hPPAR.